{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-035848","form_type":"8-K","ticker":"XFOR","cik":"0001501697","company_name":"X4 Pharmaceuticals, Inc","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.274694+00:00","generated_at":"2026-05-31T10:51:47.045973+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"X4 reports Q2 net income $90.8M on PRV sale; first XOLREMDI sales $0.6M","bullets":["Q2 net income $90.8M vs net loss $55.7M YoY; includes $105M gain on sale of priority review voucher.","First product revenue $0.6M from XOLREMDI launch following FDA approval in April 2024 for WHIM syndrome.","Cash, equivalents, marketable securities $169.5M; operating runway into late 2025 (excl. future revenue).","Positive interim Phase 2 data for mavorixafor in chronic neutropenia; full results expected Nov 2024; Phase 3 4WARD trial started.","Plans to submit EMA approval for mavorixafor in WHIM syndrome by early 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-035848","json":"https://secwatch.observer/filing/0001628280-24-035848.json","markdown":"https://secwatch.observer/filing/0001628280-24-035848.md","text":"https://secwatch.observer/filing/0001628280-24-035848.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501697/000162828024035848/0001628280-24-035848-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501697/000162828024035848/xfor-20240808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:51:47.045973+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}